Goldman Sachs asks in biotech research report: 'Is curing patients
- Reads 2
- Votes 0
- Parts 1
- Time <5 mins
- Reads 2
- Votes 0
- Parts 1
- Time <5 mins
Ongoing, First published Jun 30, 2022
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.All Rights Reserved
Sign up to add Goldman Sachs asks in biotech research report: 'Is curing patients to your library and receive updates
or
You may also like
You may also like
